GlassScriptPhysician profile
Luz N Cortes
NPI 1205897352
$3,407.38
in general payments reported to CMS, 2019-2025
38 companies · $28.01 in 2025
The $28.01 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $424 · 2021: $744 · 2022: $941 · 2023: $423 · 2024: $48.99 · 2025: $28.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $450.85 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $281.69 | 2019-2023 | Opdivo |
| Janssen Biotech, INC. | $250.09 | 2019-2023 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $214.86 | 2019-2023 | Enhertu, Imfinzi |
| Celgene Corporation | $209.70 | 2019-2023 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $201.68 | 2019-2024 | Keytruda, Welireg, Reblozyl |
| Lilly USA, LLC | $190.41 | 2019-2025 | Jaypirca, Verzenio |
| Seagen INC. | $174.04 | 2019-2023 | Tukysa |
| Genzyme Corporation | $140.02 | 2019-2023 | |
| Daiichi Sankyo INC. | $139.36 | 2019-2023 | Enhertu |
| Taiho Oncology, INC. | $125.29 | 2019-2023 | |
| Genentech USA, INC. | $114.66 | 2019-2022 | |
| Pfizer INC. | $105.74 | 2019-2022 | |
| Amgen INC. | $97.50 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $82.33 | 2019-2023 | Imbruvica |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $78.79 | 2020-2023 | Xospata |
| Puma Biotechnology, INC. | $71.59 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.35 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $57.52 | 2019-2022 | |
| Abbvie INC. | $49.79 | 2022-2024 | |
| Gilead Sciences, INC. | $33.01 | 2022-2025 | Trodelvy |
| Foundation Medicine, INC. | $25.68 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $23.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.86 | 2021 | |
| Morphosys, US INC. | $21.66 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.27 | 2021 | |
| Eisai INC. | $19.82 | 2023 | |
| Agios Pharmaceuticals, INC. | $16.45 | 2020 | |
| Verastem, INC. | $14.92 | 2019 | |
| Mirati Therapeutics, INC. | $14.78 | 2023 | Krazati |
| Beigene USA, INC. | $14.43 | 2022 | |
| Glaxosmithkline, LLC. | $12.95 | 2021 | |
| Servier Pharmaceuticals LLC | $12.93 | 2022 | |
| Exelixis INC. | $12.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.79 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.